Improved survival of multiple myeloma patients with late relapse after high‐dose treatment and stem cell support, a population‐based study of 348 patients in Denmark in 1994–2004*
- 12 August 2010
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 85 (3) , 209-216
Abstract
Objective: To analyse if patients with early relapse after high‐dose chemotherapy with stem cell support (HDT) benefit from new treatment strategies in a population‐based setting.Methods: We conducted a retrospective study of relapse treatment and survival in 348 patients undergoing HDT in Denmark in 1994–2004. Patients were divided into two groups according to time‐to‐treatment failure (i) within 18 months after HDT and (ii) later than 18 months after HDT. The fraction of patients surviving 3 yr after first relapse was evaluated in relation to calendar periods for introduction of new drugs: before the introduction of thalidomide (1995–1999), before the introduction of bortezomib and lenalidomide (2000–2002) and when patients had access to all treatment modalities (2003–2008).Results: Two hundred and forty‐three patients suffered from relapse which required treatment. The median follow‐up time was 91.4 months (60–158.8 months) and overall survival was 56.3 months after HDT. The fraction of patients alive 3 yr after first relapse increased in the periods after the year 2000 for patients with late relapse: 1995–1999, 36%; 2000–2002, 57%; and 2003–2008, 72% (P = 0.03), in contrast to patients with early relapse: 1995–1999, 25%; 2000–2002, 33%; and 2003–2008, 31% (P = 0.7).Conclusion: Improved survival was only observed among patients with late relapse after HDT and this may be because of increased use of salvage HDT, improved supportive care and introduction of new drugs.Keywords
This publication has 12 references indexed in Scilit:
- A polymorphism in NFKB1 is associated with improved effect of interferon- maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell supportHaematologica, 2009
- Treatment of newly diagnosed myelomaLeukemia, 2008
- The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCTBone Marrow Transplantation, 2008
- Impact of early relapse after auto-SCT for multiple myelomaBone Marrow Transplantation, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myelomaCancer, 2007
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantationInternational Journal of Cancer, 2006
- Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study GroupBritish Journal of Haematology, 2006